ArcherDX partners with Illumina on companion tests

LabPulse.com staff writers
Dec 2, 2019
2019 04 24 18 42 4242 Dna Blue 400

Diagnostics company ArcherDX is partnering with Illumina to develop its next-generation sequencing companion tests for oncology indications.

Boulder, CO-based ArcherDX is developing a portfolio of IVD tests for assessing targeted therapies based on genetic mutation profiles and monitoring minimal residual disease/treatment response in patients with solid and hematological malignancies.

Per the partnership, ArcherDX will secure approvals for the IVD kits and be in charge of commercialization, and the tests will be usable with Illumina's NextSeq 550Dx analyzer. The companies previously inked a similar deal to pave the way for use of the tests with Illumina's MiSeqDx system.

Latest in Hematologic Malignancies
Multiple Myeloma Social
Calculator identifies myeloma patients with favorable prognoses
May 5, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
2019 05 21 23 51 7032 Blood Cell Clot 400
FDA clears Scopio Labs hematology analysis platform
June 9, 2022
2019 05 21 23 51 7032 Blood Cell Clot 400
SeekIn receives CE Mark for karyotyping kit
April 6, 2022
Related Stories
Rare Diseases Keyboard Social
Sequencing
Illumina NGS software to enable tertiary analysis for oncology, rare disease
2019 04 17 00 53 3368 Dna Sequence 400
Molecular Diagnostics
Invitae, ArcherDX to merge
2020 05 06 20 51 7505 Lung Patient Consultation 400
Lung Cancer
FDA clears FoundationOne companion test for lung cancer drug
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Hematologic Malignancies
Calculator identifies myeloma patients with favorable prognoses
By Elissa Wolfson
An open-access calculator tool may help identify patients with more benign multiple forms of multiple myeloma, and help individualize their treatment.
May 5, 2023
Multiple Myeloma Social
Mission Bio, Abiosciences announce collaboration on hematologic cancer research applications
By LabPulse.com staff writers
They aim to combine Mission Bio’s multiomics and single-cell DNA capabilities with Abiosciences’ AI technology in finding disease signatures, identifying and addressing mechanisms of therapeutic resistance, and stratifying patients for clinical trials.
December 28, 2022
Blood Cells Vessel Social
FDA clears Scopio Labs hematology analysis platform
By LabPulse.com staff writers
Tel Aviv, Israel-based Scopio said the X100HT is a full-field digital imaging and artificial intelligence (AI)-enabled platform that combines high throughput with high resolution for hematological analysis.
June 9, 2022
2019 05 21 23 51 7032 Blood Cell Clot 400
SeekIn receives CE Mark for karyotyping kit
By LabPulse.com staff writers
Designed to show copy number alteration patterns in leukemia patients based on shallow whole-genome sequencing, the test can help hematologists make diagnoses and prognostic decisions based on European Leukemia Net, Revised International Prognostic Scoring System, or Revised International Staging System guidelines, according to the vendor.
April 6, 2022
2019 05 21 23 51 7032 Blood Cell Clot 400
Study recommends screening for adults at risk of multiple myeloma
By Leah Sherwood
"We know that in cancers such as breast cancer and lung cancer screening, early detection and early intervention can make a difference in patient survival," senior author Dr. Irene Ghobrial of the Dana-Farber Cancer Institute in Boston said in a statement. "We have shown for the first time that with highly sensitive screening techniques, it may eventually be possible to make a difference in the survival of people at elevated risk for multiple myeloma."
December 10, 2021
2021 12 10 19 28 1244 Ash 2021 Sign 400
AbbVie to deploy Adaptive's clonoSeq test in myeloma trials
By LabPulse.com staff writers
Venclexta is currently approved by the U.S. Food and Drug Administration (FDA) for use in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, and in older patients with newly diagnosed acute myeloid leukemia who can't tolerate intensive chemotherapy. It is being tested for a number of additional indications, including multiple myeloma.
December 8, 2019
2019 12 09 20 32 9244 Multiple Myeloma 400
Foundation, Natera join to develop ctDNA assays
By LabPulse.com staff writers
The ctDNA assays will be used by biopharmaceutical and clinical customers who order FoundationOne CDx, a broad companion diagnostic clinically and analytically validated for solid tumors.
September 23, 2019
2019 04 24 18 42 4242 Dna Blue 400
Page 1 of 1